Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Prothena Corp Stock (NASDAQ: PRTA) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range21.060 - 66.470 | Open / Close- / - | Float / Outstanding22.487M / 51.627M |
Vol / Avg.0 / 569.882K | Mkt Cap2.868B | P/E- | 50d Avg. Price57.490 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float22.487M | EPS-3.430 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | (EXPECTED) 2023-02-16 | |||||
REV | 31.570M |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.970 | -0.4400 | ||||
REV | 22.060M | 1.517M | -20.543M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Prothena Corp (NASDAQ: PRTA) through any online brokerage.
Other companies in Prothena Corp’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sage Therapeutics (NASDAQ:SAGE), FibroGen (NASDAQ:FGEN) and Xencor (NASDAQ:XNCR).
The latest price target for Prothena Corp (NASDAQ: PRTA) was reported by Piper Sandler on Friday, January 27, 2023. The analyst firm set a price target for 94.00 expecting PRTA to rise to within 12 months (a possible 69.22% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Prothena Corp (NASDAQ: PRTA) is $55.55 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Prothena Corp.
Prothena Corp’s Q4 earnings are confirmed for Thursday, February 16, 2023.
There is no upcoming split for Prothena Corp.
Prothena Corp is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.